Get full access to one story every week, and to summaries of all other stories. Just create a free account

Since it was founded in 1996, Indian diagnostics company Thyrocare has mostly enjoyed smooth sailing. By bringing down the cost for the most popular test for thyroid, it established itself as a serious player in the preventive healthcare space. This happened on the back of Thyrocare’s unique model—nationwide reach, but with just one lab. Samples collected throughout the length and breadth of the country were flown in to its central, automated lab for analysis.

It was a well thought out business plan—high economies of scale for one lab meant lower costs, higher margins, and, in turn, lower prices for customers. It worked wonders for the company. In 2016, Thyrocare became only the second standalone diagnostics lab to go public, after Dr Lal Path Labs, which had over 150 labs spread across the country in 2016.

But 2016 marked more than just the year of Thyrocare’s listing. It was the year that A Velumani—Thryocare’s founder, chairman, MD and CEO—decided that it was time to get closer to the patient by changing tack and building more labs. Velumani promised 25 labs by March 2018, heralding the start of big things. But two years on from that promise, Thyrocare is caught in a conundrum.

Only eight labs have been established in addition to its central lab as the company has stalled on its original vision. While the company had revenues of Rs 355.4 crore ($47.32 million) in FY18, Thyrocare’s reluctance to build more labs is on account of things not panning out the way the company had hoped. “I could build 25 labs in one year. One regional lab costs about Rs 3 crore ($423,738). Once you establish it, expenditure goes up but not revenue because there isn’t enough business. When we put labs closer to the patient in the region, we had thought more growth will happen,” says Velumani, explaining the situation.

This lack of growth is on account of forces beyond the control of Velumani and Thyrocare. In its Q3 FY18 analyst call, Thyrocare’s management had said that while the diagnostics industry grew at about 15%, the number of competitors grew at about 25%. More competition has meant less growth. From FY15 onwards, Thyrocare has seen a consistent decrease in its compound annual growth rate (CAGR). Between FY15 and FY16, this was 30.61%. This has dropped to just 11.53% between FY17 and FY18.  

In addition to the bevvy of competitors, the new labs also offered people more than what Thyrocare did. While the latter stuck to its single-minded focus on preventive care, newer labs offered both preventive as well as sick care. Preventive care only makes up 7% of the $4 billion diagnostics market, unlike the global trend, where preventive care accounts for around 60% of the entire market.

AUTHOR

Ruhi Kandhari

Ruhi writes on the impact of healthcare policies, trends in the healthcare sector and developments on the implementation of Electronic Health Records in India. She has an M. Sc. in Development Studies from the London School of Economics.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 6 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 6 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.